$4.32
10.49%
Nasdaq, Aug 22, 10:00 pm CET
ISIN
CA29286M1059
Symbol
ENGN

EnGene Stock price

$4.32
+0.46 11.92% 1M
-1.78 29.18% 6M
-2.33 35.04% YTD
-1.74 28.71% 1Y
-5.74 57.06% 3Y
-5.54 56.19% 5Y
-5.54 56.19% 10Y
-5.54 56.19% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.41 10.49%
ISIN
CA29286M1059
Symbol
ENGN
Industry

Key metrics

Basic
Market capitalization
$220.8m
Enterprise Value
$27.0m
Net debt
positive
Cash
$217.4m
Shares outstanding
51.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.0
Financial Health
Equity Ratio
87.6%
Return on Equity
-20.2%
ROCE
-35.4%
ROIC
-188.3%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-87.6m | $-114.2m
EBIT
$-88.0m | $-113.4m
Net Income
$-79.9m | $-103.9m
Free Cash Flow
$-76.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-97.1% | -84.3%
EBIT
-96.4% | -82.0%
Net Income
30.7% | -88.4%
Free Cash Flow
-61.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.6
FCF per Share
$-1.5
Short interest
0.0%
Employees
57
Rev per Employee
$0.0
Show more

Is EnGene a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

EnGene Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a EnGene forecast:

15x Buy
88%
2x Hold
12%

Analyst Opinions

17 Analysts have issued a EnGene forecast:

Buy
88%
Hold
12%

Financial data from EnGene

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Apr '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 25 25
27% 27%
-
- Research and Development Expense 63 63
151% 151%
-
-88 -88
97% 97%
-
- Depreciation and Amortization 0.37 0.37
12% 12%
-
EBIT (Operating Income) EBIT -88 -88
96% 96%
-
Net Profit -80 -80
31% 31%
-

In millions USD.

Don't miss a Thing! We will send you all news about EnGene directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

EnGene Stock News

Neutral
Business Wire
21 days ago
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today reported the grant of inducement equity awards to three newly-hired employees, with a grant date of July 31, 2025. The inducement awards consist of non-qualified stock options to purchase an aggregate 93,200 of the Company's comm...
Neutral
Business Wire
about 2 months ago
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced the appointment of three new members to its Board of Directors: Philip Astley-Sparke, William Grossman, M.D., Ph.D., and Michael Heffernan, R.Ph. Their combined experience across gene therapy, oncology, clinical devel...
Neutral
Business Wire
2 months ago
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (also known as detalimogene, and previously EG-70), the Company's lea...
More EnGene News

Company Profile

enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.

Head office Canada
CEO Ronald Cooper
Employees 57
Founded 2023
Website engene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today